Bio-Path gets patent for nucleic acid drug platform

By The Science Advisory Board staff writers

February 10, 2021 -- The U.S. Patent and Trademark Office has granted a patent to Bio-Path Holdings for its nucleic acid drug platform, expanding protections for the company's DNAbilize technology.

Bio-Path was awarded U.S. patent No. 10,898,506 titled, "P-ethoxy nucleic acids for liposomal formulation."

On February 23, the company expects to be issued U.S. patent No. 10,927,379 for its lead product candidate prexigebersen, a liposomal formulation containing the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2 (Grb2).

Researchers use modified CRISPR tool to manipulate the epigenome
Bioengineers have developed a new way to engineer the human epigenome (chemical changes in the DNA) using a modified CRISPR-Cas9 system to target and...
Improving the safety of gene therapies 2 different ways
Two groups of researchers have developed unique approaches to overcome the limitations of delivery of gene editing therapeutics. In a pair of new papers,...

Copyright © 2021

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter